<DOC>
	<DOC>NCT00523484</DOC>
	<brief_summary>This study is an observational study to see whether anxiety level can be correlated with PSA level under the current practice in the patients of prostate cancer taking hormonal therapy. For assessment of anxiety level BAI(Beck Anxiety Inventory) will be used. The target population for this study is the patients of prostate cancer diagnosed previously and who are taking hormonal therapy with regular follow-up and PSA test. The follow-up duration will be total 6 months with interim visit at 3 month and final visit at 6 month.</brief_summary>
	<brief_title>Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA &amp; BAI in prOstate Cancer patieNts</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1. Provision of written informed consent 2. Patients who take PSA test regularly 3. Observation suitable patients for PSA change according to hormonal treatment at least for 6months 4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal therapy 5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies in below: Bicalutamide Monotherapy : Bicalutamide 150mg/day Goserelin 3.6mg/10.8mg MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg 1. Prohibition use under permitted indication 2. Previous inclusion in the present study 3. Participation in a clinical study during the last 30 days</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Beck Anxiety Inventory</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Specific Antigen</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>